R

Regeneron Pharmaceuticals

Develops biopharmaceutical therapies for serious diseases

Project Specialist

Full-TimeUpdated
$67.4k - $110k/yr
Mid
Bachelor's
United States
In PersonOn-site expectations apply to many roles; confirm this role's expectations with the recruiter or hiring manager.
Project & Program ManagementProject Management

About the job

Requirements
  • An Associate Project Specialist requires a Bachelor of Science or Bachelor of Arts in business, physical or biological science, or a related field, and two years of relevant experience, or an equivalent combination of education and experience.
  • A Project Specialist requires a Bachelor of Science or Bachelor of Arts in business, physical or biological science, or a related field, and two to four years of relevant experience, or an equivalent combination of education and experience.
  • A Senior Project Specialist requires a Bachelor of Science or Bachelor of Arts in business, physical or biological science, or a related field, and four to seven years of relevant experience, or an equivalent combination of education and experience.
  • Working knowledge of project management fundamentals, including scope, schedule, risk, and stakeholder management, and the ability to apply PMO templates accurately and consistently.
  • Ability to compile, validate, and summarize project and process data, with proficiency in project management tools.
  • Clear written and verbal communication, including preparing materials for senior audiences with review.
  • Ability to manage concurrent assignments and build cross-functional relationships without direct authority.
Responsibilities
  • Maintain project schedules and RAID logs in the PMO’s standard tools and update status on the published reporting cadence.
  • Apply the standardized PMO project lifecycle and templates, including the quality, documentation, and change-control requirements of a GMP-regulated environment.
  • Track scope, schedule, and budget against the approved baseline and flag variances; do not approve baseline changes.
  • Coordinate meeting logistics, agendas, minutes, and action-item follow-through, and escalate slippage and unresolved constraints.
  • Compile project and portfolio status reporting from source data and prepare it for PMO and leadership review.
  • Maintain accurate and current project records in the PMO’s portfolio management tools and calculate and track defined key performance indicators.
  • Administer PMO governance mechanics, including stage-gate documentation, decision logs, distribution, and version control.
  • Coordinate communication across functional areas to keep participants informed of status, decisions, and required actions.
  • Draft communication and organizational change-management content for PMO review.
  • Build working relationships across IOPS functions and follow through on commitments without direct authority; surface ambiguity, competing priorities, and stakeholder conflict to the Project Manager with a recommended path forward.
Desired Qualifications
  • CAPM certification is preferred.
  • Familiarity with GMP operations and change control is preferred.

About the company

R

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops and commercializes medicines for serious diseases, with a focus on cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases. Its products come from using proprietary research capabilities and technologies to discover and develop therapies, often in collaboration with academic, research, and industry partners. Revenue comes from selling approved medicines and from licensing its technologies and entering co-development and co-commercialization partnerships. The company works with healthcare providers and regulators to ensure treatment delivery and safety. Its goal is to improve patient outcomes by bringing life-transforming medicines to market through rigorous R&D and strategic collaborations, maintaining leadership in biopharmaceutical innovation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Mount Pleasant, New York

Founded

1988

Get referred to Regeneron Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi paid $1 billion upfront, with up to $7 billion more for Regeneron's immunology pipeline.
  • Q2 2026 revenue rose 17% to $4.3 billion; Dupixent sales hit $6.0 billion.
  • Libtayo and EYLEA HD both posted record sales in Q2 2026, widening diversification.

What critics are saying

  • EYLEA biosimilar competition starts in January 2027 after Samsung's settlement.
  • Regeneron faces a 2026 SDNY securities class action over the failed fianlimab melanoma trial.
  • Dupixent's patent cliff later this decade threatens the company's biggest profit pool.

What makes Regeneron Pharmaceuticals unique

  • VelocImmune keeps generating partnered immunology assets; Sanofi renewed the alliance on October 1, 2026.
  • Dupixent remains Regeneron's engine, with over 1.5 million patients across nine indications.
  • EYLEA HD conversion shows platform strength; U.S. sales hit $596 million in Q2 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Wellness Program
  • Paid Vacation
  • Equity Awards
  • Annual Bonuses
  • Flexible Work Hours

Growth & Insights and Company News

6 month growth

1%

1 year growth

12%

2 year growth

12%
Yahoo Finance
Oct 31st, 2026
Regeneron hits two-year high as Dupixent drives $6.5B sales beat, but analysts urge caution

Regeneron Pharmaceuticals shares hit a two-year high on October 30 after a third-quarter earnings beat. The stock is now about 50% above its year-to-date low. Dupixent, developed with Sanofi, brought in roughly $6.5 billion in quarterly sales, against a consensus estimate of $6.1 billion. Regeneron reported earnings per share of $20.07 on revenue of $5.12 billion, both ahead of Street estimates. Earnings rose 70% and revenue 36%. US sales of high-dose Eylea rose 62% to $699 million. Combined US Eylea revenue still fell 1%. Analysts urge caution. Leerink Partners kept a "Market Perform" rating, and the mean price target of about $869 implies roughly 6% downside.

Yahoo Finance
Oct 31st, 2026
Regeneron Q3 revenue jumps 36% to $5.1B as Dupixent and Eylea HD sales surge

Regeneron reported third-quarter 2026 revenue of $5.1 billion, up 36% year over year, on an earnings call on October 30, 2026. Growth came from blockbuster drugs and the company's in-house genetics research engine. Sanofi reported record global Dupixent sales of $6.5 billion, up 35% at constant currency. Regeneron also extended its alliance with Sanofi to co-fund next-generation therapies. US sales of EYLEA HD, a high-dose eye treatment, reached $699 million, up 62%. The drug is offsetting weaker demand for the original formulation. In early data from 40 participants, a gene-silencing therapy for a liver disease cut liver fat by about 70% on average in 12 weeks. Regeneron plans to raise research spending by a mid-teens percentage in 2027 to fund 15 late-stage trials.

Yahoo Finance
Oct 30th, 2026
Regeneron posts record Dupixent, EYLEA HD and Libtayo sales; eyes November FDA decision on cemdisiran

Regeneron Pharmaceuticals reported record quarterly net sales for Dupixent, EYLEA HD, and Libtayo in the third quarter of 2026. It was the third straight quarter of double-digit growth in both revenue and profit. EYLEA HD now makes up nearly two-thirds of the US retinal franchise, with physician demand up 20% sequentially. Libtayo's US sales rose 81%. Regeneron expects a US Food and Drug Administration decision in November on cemdisiran for generalized myasthenia gravis. It would be the first siRNA therapy for the condition. The company expects 2027 research and development spending to rise by a mid-teens percentage to support about 15 Phase 3 trials. It also signalled a shift towards acquiring outside innovation, from early-stage platforms to commercial-stage products. Third quarter Ilaris royalty revenue included a one-off catch-up of about $60 million.

Yahoo Finance
Oct 30th, 2026
Regeneron Q3 revenue jumps 36% to $5.1B as Dupixent and Eylea HD drive growth

Regeneron Pharmaceuticals reported third-quarter revenue of $5.1 billion, up 36% year over year. Non-GAAP diluted earnings per share rose 70% to $20.07, driven by higher Sanofi collaboration revenue and growth in DUPIXENT, EYLEA HD and LIBTAYO. DUPIXENT sold more than $6.5 billion worldwide. EYLEA HD sales rose 62% to $699 million, while legacy EYLEA fell 41% to $400 million amid biosimilar competition. LIBTAYO sales grew 51% to $550 million. The company expects a US Food and Drug Administration decision in November on cemdisiran for generalized myasthenia gravis. It plans more than 15 Phase III trial starts in 2026. Regeneron expects a $1 billion upfront payment from Sanofi in the fourth quarter. It ended the quarter with $16.2 billion in cash and marketable securities, net of debt.

Yahoo Finance
Oct 30th, 2026
Regeneron jumps 13.55% on Q3 earnings beat as revenue climbs 36% to $5.1B

Regeneron shares jumped 13.55% to $929.69 on October 30, 2026, after third-quarter results beat expectations. Non-GAAP earnings per share were $20.07 against a $16.19 consensus estimate, and revenue rose 36% year over year to $5.12 billion. Sanofi collaboration revenue climbed 68% to $2.72 billion. US sales of EYLEA HD rose 62% and Libtayo grew 51%, while the company raised its full-year non-GAAP gross margin guidance to about 86%. The rally lifted sector funds. The Health Care Select Sector SPDR Fund (XLV) gained 1.8% and the iShares Biotechnology ETF (IBB) rose 1.25%. Regeneron expects a US Food and Drug Administration decision on cemdisiran next month.